FCCC LOGO Faculty Publications
Geynisman DM , Meeker CR , Doyle JL , Handorf EA , Bilusic M , Plimack ER , Wong YN
Provider and patient burdens of obtaining oral anticancer medications
Am J Manag Care. 2018 Apr 1;24(4) :e128-e133
PMID: 29668216    PMCID: PMC7596764    URL: https://www.ncbi.nlm.nih.gov/pubmed/29668216
Back to previous list
Oral anticancer medications (OAMs) are frequently used to treat patients with cancer. Unlike intravenous chemotherapy, OAMs are covered by prescription drug plans. We examined barriers to initiation of OAMs in 116 patients with prostate or kidney cancer (149 unique prescriptions). We found that the median time from initial prescription to prior authorization was 3 days and the median time from initial prescription to patient receipt of drug was 12 days. Seventy-three percent of all prescriptions required 2 or more phone calls by clinic staff and 40% required 5 or more calls. Of 107 prescriptions with data available, 54% utilized financial assistance; these required significantly more phone calls (P = .0001) and led to a longer median time to drug obtainment (P = .003) compared with those that did not require financial assistance. In those prescriptions with both initial and final co-pay information available, the initial out-of-pocket mean and median co-pays were $1226.03 and $329.73, respectively, but these dropped to $124.57 and $25.00 after utilization of co-pay assistance programs, excluding those with a $0 final co-pay. These early observations suggest that a more efficient process for initiation of OAMs is needed.
1936-2692 Geynisman, Daniel M Meeker, Caitlin R Doyle, Jamie L Handorf, Elizabeth A Bilusic, Marijo Plimack, Elizabeth R Wong, Yu Ning Journal Article United States Am J Manag Care. 2018 Apr 1;24(4):e128-e133.